Cytogenetic and molecular monitoring of residual disease in chronic myeloid leukaemia

Acta Haematologica

Volumn 107, Issue 2, 2002, Pages 64-75

  Kaeda, Jaspal ^a   Chase, Andrew ^b   Goldman, John M ^a  

^a IMPERIAL COLLEGE LONDON   (United Kingdom)

^b SALISBURY DISTRICT HOSPITAL   (United Kingdom)

Author keywords

BCR ABL; Chronic myeloid leukaemia; Fluorescence in situ hybridisation; Ph chromosome; Polymerase chain reaction; Real time polymerase chain reaction; Reverse transcriptase polymerase chain reaction

Indexed keywords

ALPHA INTERFERON; BCR ABL PROTEIN; CYTARABINE; IMATINIB; PROTEIN TYROSINE KINASE INHIBITOR;

ACCURACY; ALLOGENIC BONE MARROW TRANSPLANTATION; ARTICLE; BONE MARROW; CANCER RECURRENCE; CANCER REGRESSION; CHRONIC MYELOID LEUKEMIA; CLINICAL TRIAL; CYTOGENETICS; FLUORESCENCE IN SITU HYBRIDIZATION; GENETIC TRANSCRIPTION; HUMAN; LONG TERM CARE; METAPHASE CHROMOSOME; MINIMAL RESIDUAL DISEASE; PATIENT MONITORING; PHILADELPHIA 1 CHROMOSOME; PRIORITY JOURNAL; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; SOUTHERN BLOTTING; STEM CELL TRANSPLANTATION; TREATMENT OUTCOME; WESTERN BLOTTING;

BLOTTING, SOUTHERN; BLOTTING, WESTERN; CYTOGENETIC ANALYSIS; HUMANS; LEUKEMIA, MYELOID, CHRONIC; NEOPLASM PROTEINS; NEOPLASM, RESIDUAL; POLYMERASE CHAIN REACTION; RNA, NEOPLASM;

EID: 0036207093     PISSN: 00015792     EISSN: None     Source Type: Journal    
DOI: 10.1159/000046635     Document Type: Article

References (45)

1. Factors influencing the false positive and negative rates of BCR-ABL fluorescence in situ hybridization
2. Highly sensitive fluorescence in situ hybridization method to detect double BCR-ABL fusion and monitor response to therapy in chronic myeloid leukemia
3. A two-color BCR-ABL probe that greatly reduces the false positive and false negative rates for fluorescence in situ hybridization in chronic myeloid leukemia
4. Large deletions at the t(9;22) breakpoint are common and may identify a poor-prognosis subgroup of patients with chronic myeloid leukemia
5. Deletions of the derivative chromosome 9 occur at the time of the Ph translocation and provide a powerful and independent prognostic indicator in chronic myeloid leukemia
6. Primary chromosomal rearrangements of leukemia are frequently accompanied by extensive submicroscopic deletions and may lead to altered prognosis
7. Atypical BCR and ABL D-FISH patterns in chronic myeloid leukemia and their possible role in therapy
8. Interphase cytogenetic and competitive RT-PCR for residual disease monitoring in patients with chronic myeloid leukaemia during interferon-alpha therapy
9. Improved sensitivity of BCR-ABL detection: A triple-probe three-color fluorescence in situ hybridization system
10. Philadelphia chromosome-positive myeloid cells in the peripheral blood of chronic myelogenous leukemia patients: Comparison with the frequency detected in cycling cells of the bone marrow
11. Predominantly BCR-ABL negative myeloid precursors in interferon-alpha treated chronic myeloid leukemia: A follow-up study of peripheral blood colony-forming cells with fluorescence in situ hybridization
12. A cytogenetic and fluorescence in situ hybridization evaluation of interferon-alpha in the treatment of chronic myeloid leukemia
13. T lymphocytes in chronic myelogenous leukaemia (CML): No evidence of the BCR/ABL fusion gene detected by fluorescence in situ hybridization in 14 patients
14. A multicenter investigation with D-FISHBCR/ABL1 probes
15. Hypermetaphase fluorescence in situ hybridization for quantitative monitoring of Philadelphia chromosome-positive cells in patients with chronic myelogenous leukemia during treatment
16. Interferon-alpha produces sustained cytogenetic responses in chronic myelogenous leukemia
17. Prolonged survival in chronic myelogenous leukemia after cytogenetic response to interferon-alphatherapy
18. Predicting complete cytogenetic response in chronic myelogenous leukemia patients treated with recombinant interferon-α
19. Chronic myeloid leukemia and interferon-α: A study of complete cytogenetic responders
20. Efficacy and safety of a specific inhibitor of the BCR-ABL tyrosine kinase in chronic myeloid leukemia
21. Philadelphia chromosome breakpoints are clustered within a limited region, bcr, on chromosome 22
22. Molecular response of CML patients treated with interferon-α monitored by quantitative Southern blot analysis
23. Quantification of the breakpoint cluster region rearrangment for clinical monitoring in Philadelphia chromosome-positive chronic myeloid leukemia
24. Value of molecular monitoring during treatment of chronic myeloid leukemia: A cancer and leukemia group B study
25. Comparison of BCR-ABL protein expression and Philadelphia chromosome in patients with chronic myeloid leukemia patients
26. Quantification of residual disease in chronic myelogenous leukemia on interferon-α therapy by competitive polymerase chain reaction
27. BCR-ABL gene variants
28. Assessing residual leukaemia
29. Detection of major BCR-ABL gene expression at a very low level in blood cells of healthy individuals
30. The presence of typical and atypical BCR-ABL fusion genes in leukocytes of normal individuals: Biological significance and implications for the assessment of minimal residual disease
31. A comparison of the sensitivity of blood and bone marrow for the detection of minimal residual disease in chronic myeloid leukaemia
32. Competitive polymerase chain reaction to estimate the number of BCR-ABL transcripts in chronic myeloid leukaemia after bone marrow transplantation
33. Early detection of relapse after bone marrow transplantation in patients with chronic myelogenous leukaemia
34. Quantitation of minimal residual disease in Philadelphia chromosome positive chronic myeloid leukaemia patients using real-time quantitative RT-PCR
35. Monitoring chronic myeloid leukaemia therapy by real time quantitative PCR in blood is a reliable alternative to bone marrow cytogenetics
36. Early detection of BCR-ABL transcripts by quantitative reverse transcriptase-polymerase chain reaction predicts outcome after allogeneic stem cell transplantation for chronic myeloid leukemia
37. Molecular studies in patients with chronic myeloid leukaemia in remission 5 years after allogeneic stem cell transplant define the risk of subsequent relapse
38. Graft-versus-leukemia effect of donor lymphocyte transfusions in marrow grafted patients
39. Comparison of single-dose and escalating-dose regimens of donor lymphocyte infusion for relapse after allografting for chronic myleoid leukemia
40. Durability of responses following donor lymphocyte infusions for patients who relapse after allogeneic stem cell transplantation for chronic myeloid leukemia
41. Estimating leukemia-free survival after allografting for chronic myeloid leukemia: A new method that takes into account patients who relapse and are restored to complete remission
42. Recommendations for assessment and definitions of response and relapse in CML: A report from the chronic leukemia working committee of the IBMTR
43. Molecular heterogeneity in complete cytogenetic responders after interferon-α therapy for chronic myeloid leukemia: Low levels of minimal residual disease are associated with continuing remission
44. Chronic myeloid leukemia: Current treatment options
45. The rate and kinetics of molecular response to donor leucocyte transfusions in chronic myeloid leukaemia patients treated for relapse after allogeneic bone marrow transplantation